MedWatch

WS Audiology loses USD 600m across two years – still withholds net profit guidance

Hearing-aid manufacturer WS Audiology has operated with resounding losses in its two years after the Widex-Sivantos merger, but the executive team declines to comment on when the group expects to present black bottom-line figures. Interest-bearing debt of EUR 3.6bn makes it tough to predict, the company says.

Søren Westh Lonning, CFO of WS Audiology | Photo: WS Audiology / PR

It's been poor business as of late, to put it mildly, being hearing-aid manufacturer WS Audiology, which following the major merger of Danish Widex and EQT-owned Sivantos from Germany – which became a reality in 2019 – could otherwise claim the title as the world's third-largest hearing-aid supplier.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs